LDLR and metabolic syndrome: Cyclosporine is a well-established risk factor for dyslipidemia, as it inhibits hepatic synthesis of the LDL receptors, interferes with LDL cholesterol binding, and decreases bile acid synthesis, thereby impairing cholesterol clearance.